Motif Bio boss looks towards Phase III trials for Iclaprim

(MENAFN- ProactiveInvestors)The chief executive of Motif Bio (LON:MTFB) Graham Lumsden says the company is looking to get Phase III trials for its antibiotic drug Iclaprim up and running as quickly as possible. Today the firm told investors that American regulator the Food & Drug Administration (FDA) has given Icalprim qualified infectious diseases product (QIPD) status. This makes Iclaprim eligible for certain incentives including priority review and fast track designation.